ArticleThe pharmacogenomics journal2011
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Article in The pharmacogenomics journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response.Journal of clinical laboratory analysis · 2022Pooled it
- Analysis of genetic and clinical factors associated with buprenorphine response.Drug and alcohol dependence · 2021Pooled it
- Pooled it
- An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Distinct membrane binding properties of the two non-visual arrestins.Communications biology · 2026Article
- ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.Fundamental & clinical pharmacology · 2025Article
- Review
- Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- β-Arrestin 2 (ARRB2) Polymorphism is Associated With Adverse Consequences of Chronic Heroin Use.The American journal on addictions · 2021Article
- β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.Cell · 2020Article
- Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.British journal of clinical pharmacology · 2019Observational
- Arrestin mutations: Some cause diseases, others promise cure.Progress in molecular biology and translational science · 2019Review
- Pharmacogenetics of Opioid Use Disorder Treatment.CNS drugs · 2018Review
- Pharmacogenetics of Methadone Response.Molecular diagnosis & therapy · 2018Review
- Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.The American journal of drug and alcohol abuse · 2018Article
- A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.The pharmacogenomics journal · 2018Article
- Arresting the Development of Addiction: The Role ofThe Journal of pharmacology and experimental therapeutics · 2017Review
- Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.The pharmacogenomics journal · 2014Article
- Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.Pharmacogenomics · 2013Article
- Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.The Journal of clinical investigation · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Arrestin2 (ARRB2) is a component of the G-protein-coupled receptor complex and is involved in μ-opioid and dopamine D(2) receptor signaling, two central processes in methadone signal transduction. We analyzed 238 patients in methadone maintenance treatment (MMT) and identified a haplotype block (rs34230287, rs3786047, rs1045280 and rs2036657) spanning almost the entire ARRB2 locus. Although none of these single nucleotide polymorphisms (SNPs) leads to a change in amino-acid sequence, we found that for all the SNPs analyzed, with exception of rs34230287, homozygosity for the variant allele confers a nonresponding phenotype (n=73; rs1045280C and rs2036657G: OR=3.1, 95% CI=1.5-6.3, P=0.004; rs3786047A: OR=2.5, 95% CI=1.2-5.1, P=0.02) also illustrated by a 12-fold shorter period of negative urine screening (P=0.01). The ARRB2 genotype may thus contribute to the interindividual variability in the response to MMT and help to predict response to treatment.
Indexed as
Identifiers
20514076What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.